• Venable Expands its Patent Prosecution Capabilities in its San Francisco Office with the Addition of Benjamin Pelletier

Venable LLP is pleased to announce that Benjamin C. Pelletier has joined the firm’s growing Patent Prosecution and Counseling Practice as counsel in the San Francisco office. Mr. Pelletier’s practice focuses on clients in the biotechnology, pharmaceutical, life science, and medical device industries. Mr. Pelletier holds a J.D. from the University of California, Hastings College of the Law, an M. Eng. in bioengineering from the University of California, San Diego, and B.S. in bioengineering from the University of California, Berkeley.

Mr. Pelletier advises clients in building and protecting patent assets throughout the world, and provides strategic counseling with respect to intellectual property due diligence, freedom-to-operate issues, analysis of third-party patents, and supporting non-infringement and invalidity opinions. He holds an advanced degree in bioengineering and spent many years working at a leading biotechnology company as an engineer and project manager before attending law school. His experience broadly spans the areas of monoclonal antibodies and antibody-drug conjugates (ADCs), stem cells, tissue engineering, 3D bioprinting, biosensors, genomic sequencing, and bioinformatics, as well as companion diagnostic assay systems and devices.

Justin E. Pierce, chair of Venable’s Intellectual Property Division, said, “Ben’s addition is a key part of our strategy to expand and broaden Venable’s presence in the intellectual property sector to meet the growing needs of our client base, especially when it comes to patent prosecution in the biosciences arena.”

Commenting on his move to Venable, Mr. Pelletier said, “My clients, who typically operate at the intersections of biology, medicine, engineering, and data science, are increasingly looking for law firms that provide a comprehensive suite of legal services to them; including patent prosecution. For example, Venable’s broad experience implementing successful regulatory and food and drug law strategies perfectly complements the patent prosecution and counseling work I do for my clients.”

  • Duane Morris expands Austin office with addition of Intellectual Property Partner Pierre J. Hubert

Pierre J. Hubert has joined Duane Morris LLP’s Austin, Texas office as a partner in the firm’s  Intellectual Property practice group. Hubert further enhances the firm’s intellectual property litigation capabilities in Texas and throughout the United States. Prior to joining Duane Morris, Hubert was a principal at McKool Smith.

Duane Morris opened its Austin, Texas office in October 2017 with the addition of IP partner Bert Greene and energy sector and Trial partner Brad Thompson.

“We’re thrilled to welcome Pierre and to continue the expansion of our Austin office,”  said Thomas Sankey, managing partner of the Duane Morris offices in Austin and Houston. “[He] will be a high-quality addition to our Texas presence and to our firm.”

Hubert’s practice focuses on intellectual property litigation, including patent infringement matters in complex electrical- and computer-related technology. He is a former judicial clerk of the Court of Appeals for the Federal Circuit. He has experience in many federal district courts across the country, the Patent Trial and Appeal Board (PTAB), the International Trade Commission (ITC) and the Court of Appeals for the Federal Circuit. Hubert is the former president of the Austin Intellectual Property Law Association.

Hubert is a 1997 graduate of New York University School of Law. He earned a master’s degree (engineering) in 1993 from the University of Texas at Austin and a bachelor’s degree, cum laude, from Rice University in 1992.

  • Sterne, Kessler, Goldstein & Fox Elects Five New Directors

Sterne, Kessler, Goldstein & Fox P.L.L.C. is proud to announce the election of five new directors – Daniel Gajewski, Miklos Gaszner, M.D., Ph.D., Adam LaRock, Trey Powers, Ph.D., and Deirdre Wells – effective January 1, 2018.

“As we usher in the 40th anniversary year of our firm’s founding, the election of these five accomplished attorneys to our directorship comes at an exciting time in patent law. We value the contributions they have already made to the firm and welcome them enthusiastically to our directorship,” said Managing Director, Michael B. Ray.

  • Daniel Gajewski is a director in the Mechanical Group. His work centers on utility and design patent application prosecution, and challenges to issued patents of both types. Dan specializes in developing full product-based patent protection strategies for his clients. He is well-versed in the design idiosyncrasies of the most high-value foreign jurisdictions and works closely with local counsel in any country in which his clients seek design protection. His post-grant work with issued patents also spans both design and utility patents. He has experience challenging the validity of issued patents on behalf of his clients to protect their freedom to operate, as well as defending the patents of his clients when challenged by others. Dan earned his J.D. from The George Washington University and holds a B.S. in mechanical engineering from the University of New York at Buffalo.
  • Miklos Gaszner, M.D., Ph.D. is a director in the Biotechnology/Chemical Group. Miklos advises biotechnology and pharmaceutical companies on the development and execution of global patent strategy. He is experienced in  U.S. and international patent procurement, invalidity, noninfringement, and patentability opinions, as well as freedom-to-operate and due diligence investigations. Miklos has technical expertise in therapeutic antibodies, including antibody engineering; production and formulation; cancer treatment, including immuno oncology therapies and cancer vaccines; HIV vaccines; RNA based therapeutics, including antisense RNAs and therapeutic mRNAs; recombinant microorganisms; metabolic engineering; influenza vaccines; and food supplements. Miklos holds a J.D. degree from the American University, as well as a Ph.D. in molecular biology from Princeton University and an M.D. degree from Albert Szent-Gyorgyi Medical University.
  • Adam LaRock is a director in the Trial & Appellate Group. Adam concentrates his practice on complex patent litigation, with a particular emphasis on pharmaceutical patent litigation under the Hatch-Waxman Act. Adam has worked on cases involving pharmaceuticals (new drug compounds, enantiomers, prodrugs, salt forms, solid state forms, combinations, formulations, methods of treatment), electromechanical apparatuses, diagnostic gene testing, and near-field communication devices. He has experience in all stages of district court litigation, from pre-suit investigation through trial and appeal. Adam holds a J.D. from the University of New Hampshire, as well as a B.S. in chemistry from Clarkson University.
  • R. Wilson “Trey” Powers III, Ph.D. is a director in the Trial & Appellate and Biotechnology/Chemical Groups. He has served as counsel on over 45 inter partes review and post grant review proceedings and has extensive experience litigating before the U.S. Patent Trial and Appeal Board (PTAB). Trey also works with clients on a variety of other matters, including district court litigation, strategic IP counseling, licensing, International Trade Commission investigations under §337, evaluating patent portfolios, drafting patent applications, and prosecuting interferences. He also manages the preparation of invalidity, non-infringement, and freedom-to-operate opinions. In assisting his clients, Trey draws on significant technical experience in the areas of molecular and cellular biology, aging research, surgery, stem cell biology, microbiology, metabolic engineering, synthetic biology, and other areas of biotechnology. He holds a J.D. from the American University, a Ph.D. in molecular and cellular biology from the University of Washington, and a B.A. in biology from the University of Virginia.
  • Deirdre Wells is a director in the Trial & Appellate Group. Her practice is focused on patent litigation before federal district courts and before the International Trade Commission as well as appeals to the Federal Circuit. She has represented clients in a broad range of areas, including Hatch-Waxman Paragraph IV pharmaceuticals, chemical arts, medical devices, biotechnology, data storage devices, internet search technology, electrical connectors, wireless broadband technology, telephone systems, and mobile content delivery. Deirdre also has experience analyzing IP portfolios, representing clients in trademark and Lanham Act litigation, and formulating inter partes reexamination requests.  Deirdre holds a J.D. from Harvard Law School, as well as a B.A. in biology and French from The College of the Holy Cross.